U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
Нeparin (or Unfractionated heparin ) is an anticoagulant indicated for both the prevention and treatment of thrombotic events such as deep vein thrombosis (DVT) and pulmonary embolism (PE) as well as atrial fibrillation (AF). Heparin can also be used to prevent excess coagulation during procedures such as cardiac surgery, extracorporeal circulation or dialysis, including continuous renal replacement therapy. Heparin administration can be by intravenous (or subcutaneous route. Intravenous heparin is continuously administered for therapeutic anticoagulation, while intermittent subcutaneous administration is used to prevent thromboembolism. Once administered, heparin binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. The heparin-ATIII complex can also inactivate factors IX, XI, XII, and plasmin, but the antithrombotic effect of heparin is well correlated to the inhibition of factor Xa. Typical adverse effects from heparin use include bleeding, thrombocytopenia, injection site reactions, and other adverse effects only seen with chronic heparin administration. Bleeding is a major complication associated with heparin use. Patients should undergo monitoring for new bleeding that may present in the urine or stool. Bleeding may also present as bruising, petechial rash and nosebleeds.

CNS Activity

Curator's Comment:: The possibility of heparin penetration into brain cells was shown. The penetration occurred apparently in the form of heparin complexes with thromboplastin.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
281 nM [Kd]
607 nM [Kd]
106 nM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
HEPARIN SODIUM

Approved Use

Prophylaxis and treatment of venous thrombosis and pulmonary embolism; Prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease; Atrial fibrillation with embolization; Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); Prevention of clotting in arterial and cardiac surgery; Prophylaxis and treatment of peripheral arterial embolism. Anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures.

Launch Date

69984000000
Primary
HEPARIN SODIUM

Approved Use

Prophylaxis and treatment of venous thrombosis and pulmonary embolism; Prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease; Atrial fibrillation with embolization; Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); Prevention of clotting in arterial and cardiac surgery; Prophylaxis and treatment of peripheral arterial embolism. Anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures.

Launch Date

69984000000
Primary
HEPARIN SODIUM

Approved Use

Prophylaxis and treatment of venous thrombosis and pulmonary embolism; Prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease; Atrial fibrillation with embolization; Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); Prevention of clotting in arterial and cardiac surgery; Prophylaxis and treatment of peripheral arterial embolism. Anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures.

Launch Date

69984000000
PubMed

PubMed

TitleDatePubMed
Heparin
2021 Jan

Sample Use Guides

Deep Subcutaneous (Intrafat) Injection:
Route of Administration: Other
Substance Class Polymer
Created
by admin
on Sat Jun 26 16:53:36 UTC 2021
Edited
by admin
on Sat Jun 26 16:53:36 UTC 2021
Record UNII
T2410KM04A
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
HEPARIN
HSDB   INCI   MART.   VANDF   WHO-DD  
INCI  
Official Name English
HEPARIN [VANDF]
Common Name English
HEPARIN [HSDB]
Common Name English
SULPHATED GLYCOSAMINOGLYCANS PRESENT AS A MIXTURE OF HETEROGENEOUS MOLECULES VARYING IN MOLECULAR WEIGHTS
Common Name English
HEPARIN [INCI]
Common Name English
HEPARIN, PORCINE
Common Name English
HEPARIN [MART.]
Common Name English
HEPARIN [WHO-DD]
Common Name English
HEPARIN PORCINE INTESTINAL MUCOSA
Common Name English
SULFATED GLYCOSAMINOGLYCANS PRESENT AS A MIXTURE OF HETEROGENEOUS MOLECULES VARYING IN MOLECULAR WEIGHTS
Common Name English
Classification Tree Code System Code
WHO-ATC B01AB01
Created by admin on Sat Jun 26 16:53:36 UTC 2021 , Edited by admin on Sat Jun 26 16:53:36 UTC 2021
LOINC 42679-1
Created by admin on Sat Jun 26 16:53:36 UTC 2021 , Edited by admin on Sat Jun 26 16:53:36 UTC 2021
FDA ORPHAN DRUG 178103
Created by admin on Sat Jun 26 16:53:36 UTC 2021 , Edited by admin on Sat Jun 26 16:53:36 UTC 2021
WHO-VATC QC05BA03
Created by admin on Sat Jun 26 16:53:36 UTC 2021 , Edited by admin on Sat Jun 26 16:53:36 UTC 2021
NCI_THESAURUS C263
Created by admin on Sat Jun 26 16:53:36 UTC 2021 , Edited by admin on Sat Jun 26 16:53:36 UTC 2021
WHO-ATC B01AB51
Created by admin on Sat Jun 26 16:53:36 UTC 2021 , Edited by admin on Sat Jun 26 16:53:36 UTC 2021
FDA ORPHAN DRUG 211305
Created by admin on Sat Jun 26 16:53:36 UTC 2021 , Edited by admin on Sat Jun 26 16:53:36 UTC 2021
LOINC 66744-4
Created by admin on Sat Jun 26 16:53:36 UTC 2021 , Edited by admin on Sat Jun 26 16:53:36 UTC 2021
NDF-RT N0000006341
Created by admin on Sat Jun 26 16:53:36 UTC 2021 , Edited by admin on Sat Jun 26 16:53:36 UTC 2021
WHO-ATC C05BA03
Created by admin on Sat Jun 26 16:53:36 UTC 2021 , Edited by admin on Sat Jun 26 16:53:36 UTC 2021
WHO-ATC C05BA53
Created by admin on Sat Jun 26 16:53:36 UTC 2021 , Edited by admin on Sat Jun 26 16:53:36 UTC 2021
WHO-ATC S01XA14
Created by admin on Sat Jun 26 16:53:36 UTC 2021 , Edited by admin on Sat Jun 26 16:53:36 UTC 2021
LOINC 13055-9
Created by admin on Sat Jun 26 16:53:36 UTC 2021 , Edited by admin on Sat Jun 26 16:53:36 UTC 2021
LIVERTOX 479
Created by admin on Sat Jun 26 16:53:36 UTC 2021 , Edited by admin on Sat Jun 26 16:53:36 UTC 2021
NDF-RT N0000175474
Created by admin on Sat Jun 26 16:53:36 UTC 2021 , Edited by admin on Sat Jun 26 16:53:36 UTC 2021
WHO-ATC B01AB12
Created by admin on Sat Jun 26 16:53:36 UTC 2021 , Edited by admin on Sat Jun 26 16:53:36 UTC 2021
WHO-VATC QB01AB51
Created by admin on Sat Jun 26 16:53:36 UTC 2021 , Edited by admin on Sat Jun 26 16:53:36 UTC 2021
WHO-VATC QB01AB01
Created by admin on Sat Jun 26 16:53:36 UTC 2021 , Edited by admin on Sat Jun 26 16:53:36 UTC 2021
WHO-VATC QS01XA14
Created by admin on Sat Jun 26 16:53:36 UTC 2021 , Edited by admin on Sat Jun 26 16:53:36 UTC 2021
NDF-RT N0000175980
Created by admin on Sat Jun 26 16:53:36 UTC 2021 , Edited by admin on Sat Jun 26 16:53:36 UTC 2021
Code System Code Type Description
EVMPD
SUB02475MIG
Created by admin on Sat Jun 26 16:53:36 UTC 2021 , Edited by admin on Sat Jun 26 16:53:36 UTC 2021
PRIMARY
RXCUI
5224
Created by admin on Sat Jun 26 16:53:36 UTC 2021 , Edited by admin on Sat Jun 26 16:53:36 UTC 2021
PRIMARY
MESH
D006493
Created by admin on Sat Jun 26 16:53:36 UTC 2021 , Edited by admin on Sat Jun 26 16:53:36 UTC 2021
PRIMARY
CAS
9005-49-6
Created by admin on Sat Jun 26 16:53:36 UTC 2021 , Edited by admin on Sat Jun 26 16:53:36 UTC 2021
GENERIC (FAMILY)
ECHA (EC/EINECS)
232-681-7
Created by admin on Sat Jun 26 16:53:36 UTC 2021 , Edited by admin on Sat Jun 26 16:53:36 UTC 2021
PRIMARY
DRUG CENTRAL
1358
Created by admin on Sat Jun 26 16:53:36 UTC 2021 , Edited by admin on Sat Jun 26 16:53:36 UTC 2021
PRIMARY
NCI_THESAURUS
C539
Created by admin on Sat Jun 26 16:53:36 UTC 2021 , Edited by admin on Sat Jun 26 16:53:36 UTC 2021
PRIMARY
WIKIPEDIA
HEPARIN
Created by admin on Sat Jun 26 16:53:36 UTC 2021 , Edited by admin on Sat Jun 26 16:53:36 UTC 2021
PRIMARY
FDA UNII
T2410KM04A
Created by admin on Sat Jun 26 16:53:36 UTC 2021 , Edited by admin on Sat Jun 26 16:53:36 UTC 2021
PRIMARY
LACTMED
Heparin
Created by admin on Sat Jun 26 16:53:36 UTC 2021 , Edited by admin on Sat Jun 26 16:53:36 UTC 2021
PRIMARY
RXCUI
235473
Created by admin on Sat Jun 26 16:53:36 UTC 2021 , Edited by admin on Sat Jun 26 16:53:36 UTC 2021
ALTERNATIVE
DRUG BANK
DB01109
Created by admin on Sat Jun 26 16:53:36 UTC 2021 , Edited by admin on Sat Jun 26 16:53:36 UTC 2021
PRIMARY
IUPHAR
4214
Created by admin on Sat Jun 26 16:53:36 UTC 2021 , Edited by admin on Sat Jun 26 16:53:36 UTC 2021
PRIMARY
Display Structure of HEPARIN
Related Record Type Details
SALT/SOLVATE -> PARENT
INHIBITOR -> TARGET
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT:WEIGHT AVERAGE CHEMICAL
DEGREE OF SULFATION PHYSICAL